Ubiquitin-like polypeptide inhibits the IgE response of lipopolysaccharide-activated B cells

International Immunology
M NakamuraY Tanigawa

Abstract

Monoclonal non-specific suppressor factor (MNSF), a lymphokine produced by a murine hybridoma, was originally found to inhibit the generation of lipopolysaccharide (LPS)-induced Ig-secreting cells. Most recently, we demonstrated the recombinant form of the ubiquitin-like segment (rUbi-L) or MNSF beta, an isoform of MNSF, has a MNSF activity. To investigate the possible role of rUbi-L, a 8.5 kDa ubiquitin-like polypeptide, in the regulation of Ig isotype secretion, rUbi-L was added to purified B cell cultures stimulated with LPS plus IL-4. rUbi-L notable suppressed the IgE and IgG1 responses when added at culture initiation. In addition, rUbi-L had a strong effect on IgG3 production and a little effect on IgM production by LPS-stimulated B cells, whereas the level of other isotypes (IgG2a, IgG2b and IgA) was not affected. These findings demonstrate the isotype-specific suppression, but not pan-suppression, of Ubi-L. IFN-alpha and IFN-gamma, which are also known to inhibit the IgE response, showed a synergistic effect with Ubi-L, albeit the effects of IFN-alpha were smaller. The action was reversed by the addition of neutralizing antibodies of these cytokines. Therefore, Ubi-L, a ubiquitin-like protein, may have an important immu...Continue Reading

Citations

Feb 26, 1999·Trends in Microbiology·J C Lee
Sep 10, 2013·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Jessica A Campbell, Deborah J Lenschow
Jul 29, 2000·Biochemical and Biophysical Research Communications·M Nakamura, Y Tanigawa
May 1, 2004·Surgery·Matthias MajetschakKenneth G Proctor
Jun 11, 1999·The Journal of Biological Chemistry·M Nakamura, Y Tanigawa
Apr 16, 1998·Biochimica Et Biophysica Acta·T NagataY Tanigawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.